泰素加卡铂治疗中晚期非小细胞肺癌的临床疗效

目的：探讨泰素加卡铂联合化疗方案对非小细胞肺癌的疗效。方法：24 例中晚期非小细胞肺癌泰素135mg/m^2加卡铂300mg/m^2联合化疗，间隔28天，重复2－3次，结果：19例初治者和5例复治者近期有效率分别为68．4和40．0％，总有效率为62．5％，中位生存时间为9．2月。主要不良反应为骨髓抑制、关节或肌肉疼痛。结论：泰素加卡铁联合化疗方案对中晚期非小细胞肺癌有较好疗效，不良反应小。

The efficacy of treating intermediate and late non -small cell lung cancer with taxol plus carboplatin

Objective:To investigate the efficacy of treating taxol plus carboplatin in the treatment of non-small cell lung cancer. Methods:Twenty-four patients with intermediate and late non-small cell lung cancer were treated with combined taxol 135mg/m~ 2 and carboplatin 300mg/m~ 2 for 2-3 courses with time intervals of 28 days. Results:The response rates in 19 initial treatment cases and 5 cases treated in time of relapse were 68.4% and 40.0% respectively. The global response rate was 62.5%. The mediam survival time was 9.2 months. The main side effects were arrest of bone marrow, arthralgia and mascular pain.Conclusion:The efficacy of treating intermediate and late non-small cell lung cancer with combined taxol and carboplatin chemotherapy is fairly good. The adverse reactions are mild and tolerable.